Mocertatug rezetecan (a B7-H4 targeted antibody drug conjugate) in patients with heavily pre-treated platinum-sensitive ovarian cancer (PSOC): results of an open label, phase 2 study

International Journal of Gynecological Cancer 2026

View at publisher

Authors: Guangwen Yuan, Ge Lou, Guiling Li, Tao Zhu, Qingshui Li, Hongying Yang, Lixin Sun, An Lin, Yunong Gao, Genhai Zhu, Song Gao, Ke Wang

+5 more

Lingshuang Ren, Siyu Liu, Wenzhao Hang, Xiaoqing Zhang, Lingying Wu

DOI: 10.1016/j.ijgc.2025.103069

Cited by: 1

Fields of Study & Subjects

HER2/EGFR in Cancer Research Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy